<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01252784</url>
  </required_header>
  <id_info>
    <org_study_id>Allo-039</org_study_id>
    <nct_id>NCT01252784</nct_id>
  </id_info>
  <brief_title>Reduced-intensity Conditioning Allogeneic Hematopoietic Cell Transplantation</brief_title>
  <acronym>RICandDLI</acronym>
  <official_title>Reduced-intensity Conditioning Allogeneic Hematopoietic Cell Transplantation Followed by Prophylactic Dose-escalating Donor Lymphocyte Infusions in Higher Risk Myelodysplastic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cooperative Study Group A for Hematology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cooperative Study Group A for Hematology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the feasibility and efficacy of reduced-intensity&#xD;
      conditioning allogeneic HCT followed by prophylactic dose-escalating DLIs in patients with&#xD;
      higher risk MDS.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Conditioning therapy&#xD;
&#xD;
        -  Busulfan 3.2 mg/kg/d on d-7 to -6&#xD;
&#xD;
        -  Fludarabine 30 mg/m2 on d-7 to -2&#xD;
&#xD;
        -  ATG 1.5-3.0 mg/kg/d on d-3 to -1&#xD;
&#xD;
        -  Methylpred 2 mg/kg/d on d-4 to -1&#xD;
&#xD;
      Mobilization and harvest&#xD;
&#xD;
        -  Donor&#xD;
&#xD;
        -  G-CSF 10 mcg/kg/d s.c. on d-3 to 0&#xD;
&#xD;
        -  Harvest of PBMCs on d 0 to +1&#xD;
&#xD;
      Infuse G-PBMCs on d 0 to d+1.&#xD;
&#xD;
        -  Donor G-PBMC infusion&#xD;
&#xD;
      GVHD prophylaxis&#xD;
&#xD;
        -  Cyclosporine 1.5 mg/kg i.v. q 12 hrs beginning on d-1 and changed to oral dosing (with&#xD;
           twice the i.v. dose) when oral intake is possible. Tapered beginning between d+30 and&#xD;
           d+60.&#xD;
&#xD;
        -  Methotrexate 15 mg/m2 i.v. on d+2, and 10 mg/m2 i.v. on d+4 and d+7&#xD;
&#xD;
      Prophylactic dose-escalating DLIs&#xD;
&#xD;
        -  Begin at d+120 or at least 2 wks after IST discontinuation.&#xD;
&#xD;
        -  No evidence of recurrence or GVHD CD3+ cell dose increment q 4 wks 4Three dose levels&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2010</start_date>
  <completion_date type="Anticipated">October 2014</completion_date>
  <primary_completion_date type="Anticipated">October 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>relapse incidence,duration of remission</measure>
    <time_frame>4years</time_frame>
    <description>The efficacy of the treatment will be measured in terms of relapse incidence and duration of remission (the primary endpoints). The hematopoietic cell donors in the study will include HLA-matched sibling, HLA-matched unrelated donors, and HLA-mismatched familial donors.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>engraftment, donor chimerism, secondary graft failure,GVHD</measure>
    <time_frame>4 years</time_frame>
    <description>•This study will evaluate engraftment, donor chimerism, secondary graft failure, acute and chronic graft-versus-host disease (GVHD), immune recovery, infections, non-relapse mortality, progression-free survival (PFS), and OS.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Myelodysplastic Syndrome</condition>
  <biospec_retention>None Retained</biospec_retention>
  <biospec_descr>
    <textblock>
      This clinical trial will use busulfan, fludarabine, thymoglobulin and methylprednisolone for&#xD;
      conditioning therapy, and cyclosporine and methotrexate for prevention of GVHD. All drugs had&#xD;
      been previously accepted for administration to human in respective indication and there is no&#xD;
      need to further evaluate the efficacy and the safety of each drug separately. Dose-escalating&#xD;
      DLI is also widely accepted procedure after allogeneic HCT.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with higher risk MDS&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with higher risk MDS including chronic myelomonocytic leukemia&#xD;
&#xD;
               -  RAEB-1 or RAEB-2&#xD;
&#xD;
               -  IPSS Intermediate-2 or High risk category&#xD;
&#xD;
               -  Chronic myelomonocytic leukemia&#xD;
&#xD;
          2. Patients with appropriate hematopoietic cell donor&#xD;
&#xD;
               -  HLA-matched sibling&#xD;
&#xD;
               -  HLA-matched unrelated donor&#xD;
&#xD;
               -  HLA-mismatched familial donor 3.16 years old or older&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  • Presence of significant active infection&#xD;
&#xD;
               -  Presence of uncontrolled bleeding&#xD;
&#xD;
               -  Any coexisting major illness or organ failure&#xD;
&#xD;
               -  Patients with psychiatric disorder or mental deficiency severe as to make&#xD;
                  compliance with the treatment unlike, and making informed consent impossible&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Je-Hwan Lee, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Je-Hwan Lee, Doctor</last_name>
    <phone>82-2-3010-3218</phone>
    <email>jhlee3@amc.seoul.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ya-Eun Jang, Nurse</last_name>
    <phone>82-2-3010-6378</phone>
    <email>redpin75@paran.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Asanbyeongwon-gil, songpa-gu</state>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yae-Eun Jang, nurse</last_name>
      <phone>82-2-3010-6378</phone>
      <email>redpin75@paran.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>http://www.google.com</url>
    <description>Reduced-intensity conditioning allogeneic hematopoietic cell transplantation followed by prophylactic dose-escalating donor lymphocyte infusions in higher risk myelodysplastic syndrome</description>
  </link>
  <verification_date>November 2010</verification_date>
  <study_first_submitted>December 1, 2010</study_first_submitted>
  <study_first_submitted_qc>December 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2010</study_first_posted>
  <last_update_submitted>December 1, 2010</last_update_submitted>
  <last_update_submitted_qc>December 1, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 3, 2010</last_update_posted>
  <responsible_party>
    <name_title>COSAH</name_title>
    <organization>Cooperative Study Group A for Hematology</organization>
  </responsible_party>
  <keyword>higher risk MDS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

